Content

1

Benden C, Edwards LB, Kucheryavaya AY et al. The registry of the international society for heart and lung transplantation: sixteenth official pediatric lung and heart-lung transplantation report-2013; focus theme: age. J Heart Lung Transplant 2013; 32: 989-97.

2

Lease ED, Zaas DW. Update on infectious complications following lung transplantation. Curr Opin Pulm Med 2011; 17: 206-9.

3

Kamler M, Pizanis N. Aktueller Stand der Lungentransplantation. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 2012; 27: 235-42.

4

Bundesärztekammer. Richtlinien zur Organtransplantation gem. § 16 Abs. 1 S. 1 Nrn. 2 u. 5 TPG. Deutsches Ärzteblatt 2011; 12.

5

Pilarczyk K, Osswald BR, Pizanis N et al. Use of donors who have suffered cardiopulmonary arrest and resuscitation in lung transplantation. Eur J Cardiothorac Surg 2011; 39: 342-7.

6

Pizanis N, Gillner S, Kamler M et al. Cold-induced injury to lung epithelial cells can be inhibited by iron chelators – implications for lung preservation. Eur J Cardiothorac Surg 2011; 40: 948-55.

7

Warnecke G, Moradiellos J, Tudorache I et al. Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients. Lancet 2012; 380: 1851-8.

8

Cypel M, Yeung JC, Liu M et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364: 1431-40.

9

Aigner C, Slama A, Hotzenecker K et al. Clinical ex vivo lung perfusion–pushing the limits. Am J Transplant 2012; 12: 1839-47.

10

Egan TM, Murray S, Bustami RT et al. Development of the new lung allocation system in the United States. Am J Transplant 2006; 6: 1212-27.

11

Christie JD, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report–2010. J Heart Lung Transplant 2010; 29: 1104-18.

12

Cypel M, Yeung JC, Hirayama S et al. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant 2008; 27: 1319-25.

13

Warnecke G. Operative Technik der Lungentransplantation. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 2013; 27: 26-30.

14

Hoopes CW, Kukreja J, Golden J et al. Extracorporeal membrane oxygenation as a bridge to pulmonary transplantation. J Thorac Cardiovasc Surg 2013; 145: 862-7; discussion 7-8.

15

Christie JD, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31: 1073-86.

16

Treede H, Glanville AR, Klepetko W et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant 2012; 31: 797-804.

17

Gullestad L, Mortensen SA, Eiskjaer H et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 2010; 90: 1581-9.

18

Bhorade S, Ahya VN, Baz MA et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med 2011; 183: 379-87.

19

Euvrard S, Morelon E, Rostaing L et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-39.

20

Hillen U, Griewank K, Sommerwerck U et al. Tumor regression and sirolimus-based therapy in lung transplantation. J Heart Lung Transplant 2013; 32: 938-9.

21

Christie JD, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report–2011. J Heart Lung Transplant 2011; 30: 1104-22.

22

Jaksch P, Wiedemann D, Augustin V et al. Antithymocyte globulin induction therapy improves survival in lung transplantation for cystic fibrosis. Transpl Int 2013; 26: 34-41.

23

Gupta D, Agarwal R, Aggarwal AN et al. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. Lung India 2012; 29: S27-62.

24

Palmer SM, Limaye AP, Banks M et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152: 761-9.

25

Schlischewsky E, Fuehner T, Warnecke G et al. Clinical significance of quantitative cytomegalovirus detection in bronchoalveolar lavage fluid in lung transplant recipients. Transpl Infect Dis 2013; 15: 60-9.

26

Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011; 43: S1-S17.

27

Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-95.

28

Ruhnke M, Rickerts V, Cornely OA et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 2011; 54: 279-310.

29

Lewis RE, Viale P, Kontoyiannis DP. The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence 2012; 3: 368-76.

30

Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Medicine (Baltimore) 2012; 91: 328-36.

31

Beirao F, Araujo R. State of the art diagnostic of mold diseases: a practical guide for clinicians. Eur J Clin Microbiol Infect Dis 2013; 32: 3-9.

32

Porhownik NR. Airway complications post lung transplantation. Curr Opin Pulm Med 2013; 19: 174-80.

33

Lischke R, Pozniak J, Vondrys D, Elliott MJ. Novel biodegradable stents in the treatment of bronchial stenosis after lung transplantation. Eur J Cardiothorac Surg 2011; 40: 619-24.

34

Gottlieb J, Fuehner T, Dierich M et al. Are metallic stents really safe? A long-term analysis in lung transplant recipients. Eur Respir J 2009; 34: 1417-22.

35

Sundset A, Lund MB, Hansen G et al. Airway complications after lung transplantation: long-term outcome of silicone stenting. Respiration 2012; 83: 245-52.

36

Gordon IO, Bhorade S, Vigneswaran WT et al. SaLUTaRy: survey of lung transplant rejection. J Heart Lung Transplant 2012; 31: 972-9.

37

Greenland JR, Jones KD, Hays SR et al. Association of large-airway lymphocytic bronchitis with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2013; 187: 417-23.

38

Tait BD, Susal C, Gebel HM et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.

39

Yabu JM, Higgins JP, Chen G et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342-7.

40

Chin C, Chen G, Sequeria F et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 158-63.

41

Berry G, Burke M, Andersen C et al. Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant 2013; 32: 14-21.

42

Yousem SA, Zeevi A. The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies. Am J Surg Pathol 2012; 36: 987-92.

43

Hachem RR, Yusen RD, Meyers BF et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010; 29: 973-80.

44

Lobo LJ, Aris RM, Schmitz J, Neuringer IP. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013; 32: 70-7.

45

Snyder LD, Wang Z, Chen DF et al. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest 2013; 144: 226-33.

46

Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation 2012; 94: 775-83.

47

Lemy A, Toungouz M, Abramowicz D. Bortezomib: a new player in pre- and post-transplant desensitization? Nephrol Dial Transplant 2010; 25: 3480-9.

48

Woodle ES, Alloway RR, Girnita A. Proteasome inhibitor treatment of antibody-mediated allograft rejection. Curr Opin Organ Transplant 2011; 16: 434-8.

49

Verleden GM, Vos R, Verleden SE et al. Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation 2011; 92: 703-8.

50

Vos R, Vanaudenaerde BM, Verleden SE et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37: 164-72.

51

Finlen Copeland CA, Snyder LD, Zaas DW et al. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med 2010; 182: 784-9.

52

Weigt SS, DerHovanessian A, Wallace WD et al. Bronchiolitis obliterans syndrome: the Achilles‘ heel of lung transplantation. Semin Respir Crit Care Med 2013; 34: 336-51.

53

Jaksch P, Scheed A, Keplinger M et al. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2012; 31: 950-7.

54

Greer M, Dierich M, De Wall C et al. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Am J Transplant 2013; 13: 911-8.

55

Sato M, Waddell TK, Wagnetz U et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011; 30: 735-42.

56

Kohno M, Perch M, Andersen E et al. Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. Transplant Proc 2011; 43: 1868-70.

57

Vanaudenaerde BM, Meyts I, Vos R et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008; 32: 832-43.

58

Verleden SE, Vandermeulen E, Ruttens D et al. Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS). Semin Respir Crit Care Med 2013; 34: 352-60.

59

Langer D, Burtin C, Schepers L et al. Exercise training after lung transplantation improves participation in daily activity: a randomized controlled trial. Am J Transplant 2012; 12: 1584-92.

60

Smits JM, Nossent GD, de Vries E et al. Evaluation of the lung allocation score in highly urgent and urgent lung transplant candidates in Eurotransplant. J Heart Lung Transplant 2011; 30: 22-8.

61

Chen H, Shiboski SC, Golden JA et al. Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension. Am J Respir Crit Care Med 2009; 180: 468-74.

62

Merlo CA, Weiss ES, Orens JB et al. Impact of U.S. Lung Allocation Score on survival after lung transplantation. J Heart Lung Transplant 2009; 28: 769-75.

63

Russo MJ, Iribarne A, Hong KN et al. High lung allocation score is associated with increased morbidity and mortality following transplantation. Chest 2010; 137: 651-7.

64

DeNicola MM, Weigt SS, Belperio JA et al. Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant 2013; 32: 326-32.

65

Saini D, Weber J, Ramachandran S et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant 2011; 30: 624-31.

66

Tiriveedhi V, Angaswamy N, Brand D et al. A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection. Clin Exp Immunol 2012; 167: 158-68.

67

Kastelijn EA, van Moorsel CH, Rijkers GT et al. Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 2010; 29: 665-71.

68

Mertens V, Blondeau K, Van Oudenhove L et al. Bile acids aspiration reduces survival in lung transplant recipients with BOS despite azithromycin. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2011; 11: 329-35.

69

Paraskeva M, Bailey M, Levvey BJ et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2011; 11: 2190-6.

70

Kumar D, Husain S, Chen MH et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89: 1028-33.

71

Gottlieb J, Schulz TF, Welte T et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009; 87: 1530-7.

72

Gottlieb J, Mattner F, Weissbrodt H et al. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 2009; 103: 743-9.

73

Weigt SS, Elashoff RM, Huang C et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9: 1903-11.